WO2009139468A1 - Agent de lutte contre la coccidiose et alimentation animale le contenant - Google Patents

Agent de lutte contre la coccidiose et alimentation animale le contenant Download PDF

Info

Publication number
WO2009139468A1
WO2009139468A1 PCT/JP2009/059067 JP2009059067W WO2009139468A1 WO 2009139468 A1 WO2009139468 A1 WO 2009139468A1 JP 2009059067 W JP2009059067 W JP 2009059067W WO 2009139468 A1 WO2009139468 A1 WO 2009139468A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
mass
feed
control agent
coccidiosis
Prior art date
Application number
PCT/JP2009/059067
Other languages
English (en)
Japanese (ja)
Inventor
協 長嶋
正己 望月
Original Assignee
出光興産株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 出光興産株式会社 filed Critical 出光興産株式会社
Priority to JP2010512033A priority Critical patent/JPWO2009139468A1/ja
Publication of WO2009139468A1 publication Critical patent/WO2009139468A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Definitions

  • the present invention relates to a control agent for animal coccidiosis containing cashew nut shell liquid and / or anacardic acid and vitamins, a feed additive, a feed, and a breeding method using them.
  • the present invention further relates to a veterinary coccidiosis control agent, a feed additive, a feed, and a breeding method using these.
  • Animal coccidiosis is a protozoan parasitic infection that is transmitted by oral ingestion of oocysts (capsules of larvae). In some cases, symptoms such as intestinal lesions, diarrhea, loss of appetite, abolition, and weight loss can lead to death. In addition, coccidiosis collapses the microbial flora in the intestines, and diarrhea becomes particularly severe due to mixed infection with pathogenic bacteria. This leads to exhaustion of physical strength and susceptibility to gangrenous enteritis (bacterial infection of the lining of the intestinal tract resulting in necrosis of the intestinal lining of various regions of the gastrointestinal tract) due to reduced immunity. The ruminant coccidiosis is caused by Eimeria bovis, E.
  • chemotherapeutic agents and vaccines consisting of antibiotics (polyether antibiotics such as salinomycin) and synthetic antibacterial agents (sulfa drugs, etc.) have been mainly used.
  • antibiotics and chemotherapeutic agents have problems such as occurrence of side effects and diminished effects due to acquired resistance to drugs.
  • a vaccine it was only for prevention and could not be used for treatment.
  • humans eat meat, eggs, etc. of animals that have been administered these drugs, there is a problem of transfer of drugs remaining in the animal body to the human body, and there are severe restrictions on the amount and period of administration. It was necessary.
  • An object of the present invention is an anti-coccidial composition that is excellent in safety, has no problems such as side effects, does not cause a decrease in the effect due to acquisition of resistance to drugs, and exhibits high preventive and therapeutic effects on coccidiosis, It is to provide an animal feed containing the same and a method for preventing or treating coccidiosis in an animal using the anti-coccidial composition or feed.
  • the present inventors have found that when vitamins are used in combination with cashew nut shell liquid and / or anacardic acids, there is a further effect on the prevention and treatment of coccidiosis in animals. In particular, it was found that this tendency is remarkable in ruminants.
  • the present inventors also have a further effect of preventing and treating coccidiosis in animals by using at least one selected from calcium salts and magnesium salts in addition to cashew nut shell liquid and / or anacardic acids and vitamins. In particular, we found that this tendency is remarkable in ruminants.
  • the present inventors further effective at least one selected from maize, milo, bran, rice bran, and soybean meal. It has been found that the feed contained as a component is more effective in preventing and treating coccidiosis in animals, and the tendency is particularly remarkable in ruminants. The present inventors have thus completed the present invention.
  • the present invention is as follows.
  • An animal coccidiosis control agent comprising at least one selected from vitamin A, vitamin B, vitamin C, vitamin D, and vitamin E together with cashew nut shell liquid and / or anacardic acids.
  • the coccidiosis control agent according to (1) further comprising at least one selected from calcium salts and magnesium salts.
  • a feed additive comprising the coccidiosis control agent according to any one of (1) to (3).
  • a feed comprising the feed additive according to (4).
  • the feed according to (5) further comprising at least one selected from maize, milo, bran, rice bran, soybean meal, corn flour, rice flour, and soybean flour.
  • An animal breeding method characterized by feeding the feed according to (5) or (6).
  • a method for treating animals comprising administering cashew nut shell liquid and / or anacardic acids, and at least one selected from vitamin A, vitamin B, vitamin C, vitamin D, and vitamin E.
  • Coccidiosis of animals can be reduced by the coccidiosis control agent of the present invention, feed additives containing the same, and feed. Moreover, the weight gain and growth of an animal can be expected to be improved by the coccidiosis control agent of the present invention, a feed additive containing the same, and a feed.
  • the animal coccidiosis control agent of the present invention contains at least one selected from vitamin A, vitamin B, vitamin C, vitamin D, and vitamin E together with cashew nut shell liquid and / or anacardic acids. .
  • the cashew nut shell liquid used in the present invention is an oily liquid contained in the shell of cashew nut coconut tree (Anacardium occidentale L.).
  • Cashew nut shell oil contains anacardic acid, cardanol, and cardol as its components.
  • the cashew nut shell oil used in the present invention can be obtained as a vegetable oil extracted by pressing the cashew nut shell.
  • the cashew nut shell oil used in the present invention can also be obtained by, for example, dry distillation or solvent extraction of the cashew nut shell by heating or extraction.
  • the cashew nut shell liquid used in the present invention can be obtained by a method described in JP-A-8-231410, for example, a solvent extraction method or a heating method.
  • the cashew nut shell oil used in the present invention may be obtained by pulverizing and crushing heat sterilized oil or cashew nut shell. A commercial item can also be used for the cashew nut shell liquid used in this invention.
  • the content of cashew nut shell liquid in the coccidiosis control agent of the present invention is preferably 10% by mass to 100% by mass, more preferably 15% by mass to 100% by mass, and further preferably 20% by mass to 100% by mass. . If it is 10 mass% or more, an anti-coccidial effect can be exhibited with a predetermined amount of the control agent.
  • the content of cashew nut shell oil in the feed is preferably 0.02% by mass to 4.0% by mass, more preferably 0.04% by mass. % To 2.0% by mass, more preferably 0.06% to 1.0% by mass.
  • the cashew nut shell oil used in the present invention may be used as it is, or may be used after pulverizing and crushing the cashew nut shell containing oil, but converted into the contained cashew nut shell oil (CNSL) (
  • the cashew nut shell contains 30% CNSL), the coccidiosis control agent, and the feed content may be within the above range.
  • anacardic acids used in the present invention include natural products anacardic acid, synthetic anacardic acid, and derivatives thereof. Commercial anacardic acid may also be used.
  • anacardic acids are obtained by using cashew nut oil obtained by extracting cashew nut shells with an organic solvent by using, for example, silica gel column chromatography with n-hexane, acetic acid. It can be obtained by changing the ratio of the mixed solvent of ethyl and acetic acid (JP-A-3-240721, JP-A-3-240716, etc.).
  • Such anacardic acids have the same content as cashew nut shell liquid and can be included in the coccidiosis control agent and feed.
  • the coccidiosis control agent of the present invention contains at least one of vitamin A, vitamin B, vitamin C, vitamin D, and vitamin E, and the concentration of these vitamins in the coccidiosis control agent includes coccidiosis oocysts.
  • the amount is preferably 1 to 1,000 ppm by mass, more preferably 3 to 300 ppm by mass, and still more preferably 10 to 100 ppm by mass with respect to physiological saline containing 500 to 5000 cells / ml. However, if it is 1 mass ppm or more, an anti-coccidial effect can be exhibited with a predetermined amount of the control agent. Even when it is contained in the feed of the present invention, the same concentration may be used.
  • the coccidiosis control agent of the present invention may further contain calcium salts.
  • Calcium salts include, but are not limited to, calcium carbonate, calcium bicarbonate, calcium phosphate, calcium phosphite, fatty acid calcium, and calcium lactate.
  • the concentration of these calcium salts in the agent for controlling coccidiosis is preferably 0.1 to 10% by mass, more preferably 0.2 to 0.2% with respect to physiological saline containing 500 to 5000 coccidial oocysts / ml. It is 5% by mass, more preferably 0.4-2% by mass. However, when the content is 0.1% by mass or more, an anti-coccidial effect can be obtained with a predetermined amount of the control agent. Even when it is contained in the feed of the present invention, the same concentration may be used.
  • the coccidiosis control agent of the present invention may further contain magnesium salts.
  • Magnesium salts include, but are not limited to, magnesium oxide, magnesium sulfate, magnesium carbonate, and magnesium chloride.
  • the concentration contained in these agents for controlling coccidiosis is preferably 0.1 to 10% by mass, more preferably 0.2 to 5% with respect to physiological saline containing 500 to 5,000 oocysts of coccidium / ml. % By mass, more preferably 0.4 to 2% by mass.
  • the content is 0.1% by mass or more, an anti-coccidial effect can be obtained with a predetermined amount of the control agent. Even when it is contained in the feed of the present invention, the same concentration may be used.
  • the animals targeted by the coccidiosis control agent of the present invention are preferably ruminants such as cattle, goats and sheep, and birds such as chickens and turkeys, but are not limited thereto.
  • the term “control” includes prevention and treatment.
  • bacteria that cause coccidiosis in chickens that are targets of the agent for controlling coccidiosis of the present invention include Eimeria tenella, E. acervulina, E. necatrix, Eimeria. Brunetti (E. brunetti), Eimeria Maxima (E. maxima), Eimeria Mivati (E. mivati), Eimeria Mitis (E. mitis), Eimeria Precox (E. precox), Eimeria Hagani (E. hagani) and the like, and the bacteria causing turkey coccidiosis include E. meleagrimitis, E. adenoides, E. gallopovonis, etc. .
  • the bacteria causing coccidiosis in cattle include Eimeria bovis, E. zuernii, E. auburnensis, E. ellipsoidalis, and Eimeria alloingi. (E. arloingi), Eimeria ovina (E. ovina) and the like.
  • the dosage form of the coccidiosis control agent of the present invention is not particularly limited, and may be any form such as powder, liquid, solid, tablet, capsule, and emulsion.
  • the coccidiosis control agent of the present invention can be produced by mixing cashew nut shell liquid, vitamins, and, if necessary, optional components and preparing a formulation.
  • the above-mentioned cashew nut shell can be ground or crushed, or the cashew nut shell can be directly mixed with other optional components without any treatment to provide the coccidiosis control agent of the present invention.
  • the crushed and crushed material itself or the cashew nut shell itself and vitamins A to E alone can be used as a feed additive and further as a feed.
  • the feed additive of the present invention can be mixed with other feed ingredients used in pet food and pet supplements (hereinafter referred to as feed) to obtain feed.
  • feed used in pet food and pet supplements
  • the type of feed and ingredients other than cashew nut shell liquid are not particularly limited.
  • the feed is preferably for ruminants.
  • the feed of the present invention can be produced by adding a feed additive to a feed component as it is and mixing them.
  • the feed additive may be in a liquid or gel form for easy mixing.
  • water, vegetable oils such as soybean oil, rapeseed oil and corn oil, liquid animal oils, water-soluble polymer compounds such as polyvinyl alcohol, polyvinyl pyrrolidone and polyacrylic acid can be used as the liquid carrier.
  • a water-soluble polysaccharide such as alginic acid, sodium alginate, xanthan gum, sodium caseinate, gum arabic, guar gum, tamarind seed polysaccharide.
  • the feed of the present invention may contain maize, milo, bran, rice bran, soybean meal, corn flour, rice flour, soybean flour and the like.
  • concentration in these feeds is preferably 1 to 90% by mass, more preferably 5 to 75% by mass, and still more preferably 10 to 50% by mass. If it is 1 mass% or more, an anti-coccidial effect can be produced, and if it is 90 mass% or less, the performance as a feed can be maintained, which is preferable.
  • the feed of the present invention may further contain optional components such as a component effective for promoting the growth of ruminants, a nutritional supplement component, and a component that enhances storage stability.
  • optional components include, for example, viable agents such as enterococcus, bacillus, bifidobacteria and lactobacillus; enzymes such as amylase and lipase; vitamins such as choline chloride, inositol and folic acid; potassium chloride and citric acid Minerals such as iron and phosphates; amino acids such as DL-alanine, DL-methionine, and L-lysine hydrochloride; organic acids such as fumaric acid, butyric acid, lactic acid, acetic acid and their salts; and anti-oxidants such as ethoxyquin and dibutylhydroxytoluene Oxidizing agents; antifungal agents such as propionic acid and sodium propionate; binders such as CMC, sodium caseinate and sodium polyacryl
  • the type of animal that receives the feed of the present invention is preferably a ruminant.
  • the feed of the present invention is suitable for breeding ruminants such as cows, goats and sheep.
  • the amount of feed to be ingested can be appropriately adjusted according to the kind of animal, body weight, age, sex, health condition, ingredients of the feed, etc., and cashew nut nut shell oil and / or anacardic acids contained in the feed are preferable. 0.005 to 500 g / head / day, more preferably 0.05 to 100 g / head / day, and still more preferably 0.5 to 50 g / head / day.
  • a method for ingesting and rearing a feed a commonly used method can be employed depending on the type of animal.
  • Cashew nut shells were obtained from the coccidiosis control agent or feed of the present invention from Cashew Trading Co., Ltd.
  • Cashew nut shell oil (CNSL) was obtained by pressing and extracting the shell.
  • BREDOL 694 as a surfactant was obtained from Pacific Science Co., Ltd.
  • vitamin A (Example 1), vitamin B (Example 2), vitamin C (Example 3), vitamin D (Example 4), or vitamin E (Example 5), or Vitamin E and calcium carbonate (Example 6), calcium phosphate (Example 7), or magnesium oxide (Example 8) and CNSL and BREDOL 694 are combined to form the coccidiosis control agent of the present invention, or vitamin E, Calcium carbonate, bran (Example 9), rice bran (Example 10), soybean meal (Example 11) or corn flour (Example 12), and CNSL and BREDOL694 were used in combination as feed for the present invention.
  • Coccidial control test Cattle diarrhea stool naturally infected with Eimeria zuernii was collected, and oocysts were separated under a stereomicroscope and washed with physiological saline. 5 ml of physiological saline was added to a petri dish having a diameter of 9 cm, and washed oocysts were added to 2000 pieces / ml. A petri dish without any addition was used as a control.
  • a group in which 0.5% by mass of CNSL and 0.5% by mass of BREDOL694 were added was defined as Comparative Example 1.
  • a group in which 0.5 mass% of BREDOL694 and 100 mass ppm of vitamin A were added was defined as Comparative Example 2.
  • a group in which 0.5 mass% of BREDOL694 and 100 mass ppm of vitamin B were added was defined as Comparative Example 3.
  • a group in which 0.5 mass% of BREDOL694 and 100 mass ppm of vitamin C were added was defined as Comparative Example 4.
  • a group in which 0.5% by mass of BREDOL694 and 100 ppm by mass of vitamin D were added was defined as Comparative Example 5.
  • a group in which 0.5 mass% of BREDOL694 and 100 mass ppm of vitamin E were added was defined as Comparative Example 6.
  • a group in which 0.5% by mass of BREDOL694 and 1% by mass of calcium carbonate were added was defined as Comparative Example 7.
  • Comparative Example 8 was obtained by adding 0.5% by mass of BREDOL694 and 1% by mass of calcium phosphate.
  • Comparative Example 9 A group in which 0.5% by mass of BREDOL694 and 1% by mass of magnesium oxide were added was defined as Comparative Example 9. A group in which 0.5% by mass of BREDOL694 and 20% by mass of bran were added was defined as Comparative Example 10. Comparative Example 11 was obtained by adding 0.5% by mass of BREDOL694 and 20% by mass of rice bran. A group in which 0.5% by mass of BREDOL694 and 20% by mass of soybean meal were added was designated as Comparative Example 12. Comparative Example 13 was obtained by adding 0.5% by mass of BREDOL694 and 20% by mass of corn flour. A group in which 0.5 mass% of CNSL, 0.5 mass% of BREDOL 694, and 100 mass ppm of vitamin A were added was defined as Example 1.
  • Example 2 A group in which 0.5% by mass of CNSL, 0.5% by mass of BREDOL694 and 100 mass ppm of vitamin B were added was defined as Example 2.
  • Example 3 A group in which 0.5 mass% of CNSL, 0.5 mass% of BREDOL 694, and 100 mass ppm of vitamin C were added was defined as Example 3.
  • Example 4 A group in which 0.5 mass% of CNSL, 0.5 mass% of BREDOL 694, and 100 mass ppm of vitamin D were added was defined as Example 4.
  • Example 5 A group in which 0.5 mass% of CNSL, 0.5 mass% of BREDOL 694, and 100 mass ppm of vitamin E were added was defined as Example 5.
  • Example 6 A group in which 0.5% by mass of CNSL, 0.5% by mass of BREDOL694, 100% by mass of vitamin E and 1% by mass of calcium carbonate were added was defined as Example 6.
  • Example 7 A group in which 0.5% by mass of CNSL, 0.5% by mass of BREDOL694, 100% by mass of vitamin E and 1% by mass of calcium phosphate were added was defined as Example 7.
  • Example 8 A group in which 0.5% by mass of CNSL, 0.5% by mass of BREDOL694, 100% by mass of vitamin E and 1% by mass of magnesium oxide were added was defined as Example 8.
  • Example 9 was prepared by adding 0.5% by mass of CNSL, 0.5% by mass of BREDOL694, 100% by mass of vitamin E, 1% by mass of calcium carbonate, and 20% by mass of bran.
  • Example 10 was prepared by adding 0.5% by mass of CNSL, 0.5% by mass of BREDOL694, 100% by mass of vitamin E, 1% by mass of calcium carbonate, and 20% by mass of rice bran.
  • Example 11 was prepared by adding 0.5% by mass of CNSL, 0.5% by mass of BREDOL694, 100% by mass of vitamin E, 1% by mass of calcium carbonate, and 20% by mass of soybean meal.
  • a group in which 0.5% by mass of CNSL, 0.5% by mass of BREDOL694, 100% by mass of vitamin E, 1% by mass of calcium carbonate, and 20% by mass of corn flour were added as Example 12.
  • the petri dish was allowed to stand at 37 ° C. for 7 days and observed in a timely manner. Seven days later, the sample was observed under a stereomicroscope to measure the number of oocysts and the state of cell wall deformation and dissolution. The results are shown in Table 1.
  • the combination of CNSL and vitamins A, B, C, D, or E clearly decreased the number of Eimeria zuernii oocysts compared to the comparative example.
  • the combination of CNSL and vitamin E with calcium carbonate, calcium phosphate, or magnesium oxide further clearly reduced the number of oocysts in Eimeria zuernii compared to the comparative example, and the remaining oocysts Dissolution deformation was observed.
  • the coccidiosis of an animal can be controlled by the coccidiosis control agent of the present invention, an additive containing the same, and feed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur un agent pour lutter contre la coccidiose chez un animal, qui est caractérisé par le fait qu'il comprend une huile de coque de noix de cajou et/ou de l'acide anacardique et au moins un élément choisi parmi la vitamine A, la vitamine B, la vitamine C, la vitamine D et la vitamine E.
PCT/JP2009/059067 2008-05-16 2009-05-15 Agent de lutte contre la coccidiose et alimentation animale le contenant WO2009139468A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010512033A JPWO2009139468A1 (ja) 2008-05-16 2009-05-15 コクシジウム症防除剤およびそれを含有する飼料

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008129244 2008-05-16
JP2008-129244 2008-05-16

Publications (1)

Publication Number Publication Date
WO2009139468A1 true WO2009139468A1 (fr) 2009-11-19

Family

ID=41318826

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/059067 WO2009139468A1 (fr) 2008-05-16 2009-05-15 Agent de lutte contre la coccidiose et alimentation animale le contenant

Country Status (3)

Country Link
JP (1) JPWO2009139468A1 (fr)
TW (1) TW201006467A (fr)
WO (1) WO2009139468A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011152532A1 (fr) * 2010-06-03 2011-12-08 出光興産株式会社 Baume de cajou ayant une stabilité améliorée
US9730971B2 (en) 2008-12-12 2017-08-15 Idemitsu Kosan Co., Ltd. Feed for preventing and/or treating diseases caused by clostridium bacterium in livestock, and agent against clostridium
WO2021085584A1 (fr) 2019-10-31 2021-05-06 出光興産株式会社 Inhibiteur de résistance à l'insuline pour animaux ruminants
WO2021112171A1 (fr) 2019-12-03 2021-06-10 出光興産株式会社 Agent anti-inflammatoire pour cellule intestinale
CN113412057A (zh) * 2019-02-08 2021-09-17 出光兴产株式会社 功能性饲料
WO2022250027A1 (fr) 2021-05-28 2022-12-01 株式会社エス・ディー・エス バイオテック Agent anti-inflammatoire pour cellules intestinales d'un animal domestique

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61280239A (ja) * 1985-06-03 1986-12-10 Ajinomoto Co Inc 反すう動物の輸送、移動方法
JPH0347043A (ja) * 1989-07-14 1991-02-28 Miyoshi Oil & Fat Co Ltd 反すう動物用飼料添加物
JPH08231410A (ja) * 1995-02-23 1996-09-10 Takasago Internatl Corp コクシジウム症軽減剤及びそれを含有する飼料
JP2001151675A (ja) * 1999-11-26 2001-06-05 Nisshin Flour Milling Co Ltd コクシジウム症の予防および／または治療用飼料
JP2003238400A (ja) * 2002-02-12 2003-08-27 Nippon Zenyaku Kogyo Kk 抗コクシジウム組成物及びそれを含有する飼料
JP2006141270A (ja) * 2004-11-19 2006-06-08 Bio Kagaku Kk 反すう動物用ルーメンバイパス剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3323466B2 (ja) * 1999-12-09 2002-09-09 日清製粉株式会社 反芻動物用飼料

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61280239A (ja) * 1985-06-03 1986-12-10 Ajinomoto Co Inc 反すう動物の輸送、移動方法
JPH0347043A (ja) * 1989-07-14 1991-02-28 Miyoshi Oil & Fat Co Ltd 反すう動物用飼料添加物
JPH08231410A (ja) * 1995-02-23 1996-09-10 Takasago Internatl Corp コクシジウム症軽減剤及びそれを含有する飼料
JP2001151675A (ja) * 1999-11-26 2001-06-05 Nisshin Flour Milling Co Ltd コクシジウム症の予防および／または治療用飼料
JP2003238400A (ja) * 2002-02-12 2003-08-27 Nippon Zenyaku Kogyo Kk 抗コクシジウム組成物及びそれを含有する飼料
JP2006141270A (ja) * 2004-11-19 2006-06-08 Bio Kagaku Kk 反すう動物用ルーメンバイパス剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AKIRA CHAZONO ET AL.: "Arushu Vitamin-zai no Renzoku Toyo ga Niwatori Coccidium Jinko Kansen Niwatori no Zotai to Byohen ni Oyobosu Koka", ANIMAL HUSBANDRY, vol. 32, no. 7, 1978, pages 862 - 866 *
H.S.RIREHOI ET AL.: "Shiryo Eiyoso ni yoru Coccidium Bogyo no Kanosei n-3 Shibosan ga Ichibu no Coccidium Yokusei ni Koka", THE NIWATORI-NO- KENKYU, vol. 75, no. 12, 2000, pages 59 *
JUN'YA TSUNEOKA ET AL.: "Kuroge Washu Hiiku Gyu ni Okeru Coccidium-byo Taisaku", NAGASAKI-KEN KACHIKU HOKEN EISEI GYOSEKI HAPPYOKAI SHUROKU, vol. 45, 2003, pages 51 - 54 *
RYO OGAWA ET AL.: "Kuroge Washu Gyu no Funbenchu Coccidial Oocyst-su no Zoka ni Kansuru Yoin", NAGASAKI-KEN KACHIKU HOKEN EISEI GYOSEKI HAPPYOKAI SHUROKU, vol. 46, 2004, pages 35 - 38 *
TAKAKO MURANO ET AL.: "Niwatori Coccidium-byo to Sogo Vitamin-zai no Toyo Jiki no Kankei ni Tsuite", BULLETIN OF THE CHIBA PREFECTURAL LIVESTOCK EXPERIMENT STATION, no. 7, 1983, pages 13 - 18 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9730971B2 (en) 2008-12-12 2017-08-15 Idemitsu Kosan Co., Ltd. Feed for preventing and/or treating diseases caused by clostridium bacterium in livestock, and agent against clostridium
WO2011152532A1 (fr) * 2010-06-03 2011-12-08 出光興産株式会社 Baume de cajou ayant une stabilité améliorée
CN102933696A (zh) * 2010-06-03 2013-02-13 出光兴产株式会社 稳定性提高的腰果壳油
AU2011259858B2 (en) * 2010-06-03 2015-01-22 Sds Biotech K.K. Cashew nut shell liquid having improved stability
CN113412057A (zh) * 2019-02-08 2021-09-17 出光兴产株式会社 功能性饲料
WO2021085584A1 (fr) 2019-10-31 2021-05-06 出光興産株式会社 Inhibiteur de résistance à l'insuline pour animaux ruminants
KR20220092505A (ko) 2019-10-31 2022-07-01 이데미쓰 고산 가부시키가이샤 반추 동물의 인슐린 저항성 억제제
WO2021112171A1 (fr) 2019-12-03 2021-06-10 出光興産株式会社 Agent anti-inflammatoire pour cellule intestinale
WO2022250027A1 (fr) 2021-05-28 2022-12-01 株式会社エス・ディー・エス バイオテック Agent anti-inflammatoire pour cellules intestinales d'un animal domestique

Also Published As

Publication number Publication date
TW201006467A (en) 2010-02-16
JPWO2009139468A1 (ja) 2011-09-22

Similar Documents

Publication Publication Date Title
JP5424401B2 (ja) 反芻動物の鼓脹症防除剤
JP5611203B2 (ja) コクシジウム症防除剤およびそれを含有する飼料
Ajiboye et al. A perspective on the ingestion and nutritional effects of feed additives in farmed fish species
JP5634261B2 (ja) 飼料用組成物およびそれを含有する飼料
JP5853067B2 (ja) 反芻動物の周産期病の予防または治療剤
WO2009139468A1 (fr) Agent de lutte contre la coccidiose et alimentation animale le contenant
JP5484340B2 (ja) 反芻動物の鼓脹症治療剤
JP7041304B2 (ja) 機能性飼料
WO2010113886A1 (fr) Agent pour favoriser le gain de poids chez du bétail, aliments et procédé pour favoriser le gain de poids
WO2015056729A1 (fr) Aliment fonctionnel
JP2015030717A (ja) 飼料添加物および飼料
CN114599231B (zh) 反刍动物的胰岛素抵抗性抑制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09746674

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010512033

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09746674

Country of ref document: EP

Kind code of ref document: A1